Seikagaku Corp.

DUBLIN, June 22, 2023 /PRNewswire/ -- The "Global Cancer Vaccine Partnering Terms and Agreements 2010-2023" report has been added to ResearchAndMarkets.com's offering. The Global Cancer Vaccine Partnering Terms and Agreements 2010-2023 report provides comprehensive access to available deals and contract documents for over 350 cancer vaccine deals. Trends in cancer vaccine partnering deals Disclosed headlines, upfronts, milestones and royalties by stage of development Cancer vaccine partnering contract documents Top cancer vaccine deals by value This report provides details of the latest cancer vaccine agreements announced in the life sciences since 2010. The report takes the reader through a comprehensive review cancer vaccine deal trends, key players, top deal values, as well as deal financials, allowing the understanding of how, why and under what terms, companies are entering cancer vaccine partnering deals. The report presents financial deal term values for cancer vaccine deals, listing by headline value, upfront payments, milestone payments and royalties, enabling readers to analyse and benchmark the financial value of deals. The middle section of the report explores the leading dealmakers in the cancer vaccine partnering field; both the leading deal values and most active cancer vaccine dealmaker companies are reported allowing the reader to see who is succeeding in this dynamic dealmaking market. One of the key highlights of the report is that over 350 online deal records of actual cancer vaccine deals, as disclosed by the deal parties, are included towards the end of the report in a directory format - by company A-Z, stage of development, deal type, therapy focus, and technology type - that is easy to reference. Each deal record in the report links via Weblink to an online version of the deal. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners. Whilst many companies will be seeking details of the payment clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases and databases do not. The initial chapters of this report provide an orientation of cancer vaccine dealmaking. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in cancer vaccine dealmaking since 2010, including details of headline, upfront, milestone and royalty terms. Chapter 3 provides a review of the leading cancer vaccine deals since 2010. Deals are listed by headline value. Where the deal has an agreement contract published at the SEC a link provides online access to the contract. Chapter 4 provides a comprehensive listing of the top 25 most active companies in cancer vaccine dealmaking with a brief summary followed by a comprehensive listing of cancer vaccine deals announced by that company, as well as contract documents, where available. Chapter 5 provides a comprehensive and detailed review of cancer vaccine partnering deals signed and announced since Jan 2010, where a contract document is available in the public domain. Each deal title links via Weblink to an online version of the deal record and contract document, providing easy access to each contract document on demand. Chapter 6 provides a comprehensive and detailed review of cancer vaccine partnering deals signed and announced since Jan 2010. The chapter is organized by specific cancer vaccine technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each deal on demand. A comprehensive series of appendices is provided organized by cancer vaccine partnering company A-Z, stage of development, deal type, and therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each deal on demand. The report also includes numerous tables and figures that illustrate the trends and activities in cancer vaccine partnering and dealmaking since 2010. In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of cancer vaccine technologies and products. Key benefits In-depth understanding of cancer vaccine deal trends since 2010 Access to headline, upfront, milestone and royalty data Detailed access to actual cancer vaccine contracts entered into by leading biopharma companies Identify most active cancer vaccine dealmakers since 2010 Insight into terms included in a cancer vaccine partnering agreement, with real world examples Understand the key deal terms companies have agreed in previous deals Undertake due diligence to assess suitability of your proposed deal terms for partner companies In Global Cancer Vaccine Partnering Terms and Agreements 2010-2023, the available deals are listed by: Company A-Z Headline value Stage of development at signing Deal component type Specific therapy target Technology type Analyzing actual contract agreements allows assessment of the following: What are the precise rights granted or optioned? What is actually granted by the agreement to the partner company? What exclusivity is granted? What is the payment structure for the deal? How are sale sand payments audited? What is the deal term? How are the key terms of the agreement defined? How are IPRs handled and owned? Who is responsible for commercialization? Who is responsible for development, supply, and manufacture? How is confidentiality and publication managed? How are disputes to be resolved? Under what conditions can the deal be terminated? What happens when there is a change of ownership? What sublicensing and subcontracting provisions have been agreed? Which boilerplate clauses does the company insist upon? Which boilerplate clauses appear to differ from partner to partner or deal type to deal type? Which jurisdiction does the company insist upon for agreement law? Companies Mentioned 2A 3D Medicines A*STAR Bioprocessing Technology Institute Aura Biosciences Averion AV Therapeutics Beth Israel Deaconess Medical Center BGI CureLab Oncology CureVac Cyplasin Biomedical CYTLIMIC Daiichi Sankyo Dainippon Sumitomo Pharma Dalton Pharma Services Exiqon ExpreS2ion Biotechnologies Federal Ministry of Education and Research (BMBF) Flaskworks Georgia Health Sciences University GeoVax German Cancer Research Center Hookipa Pharma Human Vaccines Project iBio Icahn School of Medicine at Mount Sinai Ichor Medical Systems Leukaemia & Lymphoma Research LG Life Sciences Ligand Pharmaceuticals Massachusetts Life Sciences Center Mayo Clinic National Research Council Canada National Surgical Adjuvant Breast and Bowel Project OncoQR OncoSec Medical Oncotherapy Science PsiOxus Therapeutics Pulmotec PX Biosolutions Qiagen Radboud University Nijmegen Medical Centre Selecta Biosciences Selexis Sellas Clinicals Holding Seres Therapeutics Telormedix Teva Pharmaceutical Industries VGX International Vinnova ViroMed Vivalis VLP Therapeutics VLST Corporation Y-mAbs Therapeutics Yale University Yamaguchi University For more information about this report visit About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Contact: Research and Markets Laura Wood, Senior Manager [email protected] For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716 Logo: SOURCE Research and Markets

DUBLIN, June 8, 2023 /PRNewswire/ -- The "Regenerative Medicines: Bone and Joint Applications" report has been added to ResearchAndMarkets.com's offering. The global market for regenerative medicine for bone and joint applications was valued at $9.6 billion in 2022. By technology, this market is segmented into biomaterials, stem cell therapy, and tissue engineering. The tissue engineering segment recorded $2.4 billion in revenue in 2022 and is expected to grow at a compound annual growth rate (CAGR) of 13.3% during the forecast period. This study looks at most of the systems affected by factors such as R&D spending and increasing competition and new technologies. This report also covers merger and acquisition strategies and collaborations, as well as the strengths and weaknesses of each strategy type. The report provides information to all market players, potential entrants, government agencies, and other interested parties. Regenerative medicine is an emerging technology that is set to revolutionize healthcare. Regenerative medicine aims to develop processes and methods to regrow, regenerate or repair diseased or damaged cells, tissues, or organs. The rapid growth rate of the tissue engineering segment is attributed to the growing adoption of products designed and developed for treating tissues such as bone, skeletal muscle, cartilage, blood vessel, nerve tissue, skin, and for complete organs. According to the American Academy of Orthopedic Surgeons (Annual Report 2022), hip and knee arthroplasty procedures continue to increase. The market for regenerative medicine for bone and joint applications is expected to display substantial growth during the forecast period, supported by an increasingly aging population worldwide, the growing occurrence of arthritic conditions such as osteoporosis and osteoarthritis, and an increasing number of orthopedic surgeries. According to WHO, osteoporosis affects approximately 6.3% of men over the age of 50 and 21.2% of women over the same age range globally. According to International Osteoporosis Foundation, by 2050, the worldwide incidence of hip fracture in men is projected to increase by 310% and 240% in women, compared to 1990. The market has been established in North America and Europe, which currently are the leaders in revenue sharing. However, the growth opportunities are better in emerging economies, especially Brazil, Russia, India, and China (BRIC) nations, due to an increased level of awareness as well as an increase in per capita income. Moreover, the increased focus of manufacturers toward emerging economies and innovative formulas to sell in emerging markets are further boosting the market's growth. The major players in the market are Smith & Nephew, DePuy Synthes, Medtronic plc, Stryker Corp., Bioventus, Zimmer Biomet, Anika Therapeutics, Baxter, and CONMED Corp. Report Includes Analyses of the global market trends, with historical market revenue data (sales figures) for 2020-2022, estimates for 2023, and projections of compound annual growth rates (CAGRs) through 2028 Estimation of the actual market size and revenue forecast for regenerative medicine for bone and joint applications market, and corresponding market share analysis based on the type of technology, application, and region Highlights of the importance of biomaterials, stem cell therapy, tissue engineering, and emerging/upcoming technologies (including bioprinting) in the regenerative medicine industry, along with the long-term impacts of regenerative medicine technologies, both existing and in developmental stage Country specific data analysis and market growth forecasts for the U.S., Canada, Germany, the UK, France, Italy, Russia, Spain, Australia, Japan, China and India Discussion of major growth drivers and restraints, technology advancements, product innovations and regulatory aspects that will shape the market for regenerative medicine for bone and joint applications as a basis for projecting demand in the next few years (2023-2028) Identification of the companies best positioned to meet this demand owing to or in conjunction with their proprietary technologies, product launches, and other strategic advantages Holistic review of the impact of COVID-19 and other economic and demographic factors affecting the market growth in the analysis period A relevant patent analysis with the number of patents registered/approved, ongoing industry clinical trials, and recent mergers, acquisitions, and collaboration agreements in the regenerative medicine industry Insight into the recent industry structure, competitive aspects of each product segments, increasing investment on global R&D activities, market growth strategies, and company revenue share analysis Identification of leading and emerging competitors in the global regenerative medicine market, and analysis of competitive landscape based on recent developments and segmental revenues Company profiles descriptions of the major market players, including Smith & Nephew Plc, DePuy Synthes, Medtronic plc, Stryker Corp., Bioventus, Zimmer Biomet, Anika Therapeutics, Baxter Intl., and CONMED Corp. Key Topics Covered: Chapter 1 Introduction Chapter 2 Summary and Highlights Chapter 3 Market and Technology Background Overview of Regenerative Medicine How Regenerative Medicine Works? Principal Approaches to Regenerative Medicine Cells and Tissues Tissue Engineering Importance of Scaffolding in Tissue Engineering Plastic Scaffolding Blood Vessel Scaffolding Center for Integration of Medicine and Innovative Technology (Cimit) Embryonic Stem Cells Chapter 4 Emerging/Upcoming Technologies in the Market Emerging Technologies in Regenerative Medicines for Bones and Joint Applications Nanomaterials and Regenerative Medicine in Orthopedic Surgery Regeneration Therapy Using Stem Cells and Nanometer Technology Nanostructured Cartilage Tissue Engineering Bone Tissue Engineering Tendon Tissue Engineering Adipose Tissue Platelet-Rich-Plasma (Prp) Bioprinting Technologies for Construction of Multicellular/Multi-Material Tissues Scaffolding Option in Tissue Engineering Hydrogel Scaffold Solid Scaffold Future Opportunities Chapter 5 Market Dynamics Market Drivers Growing Number of Bone and Joint Disorders and Orthopedic Surgeries Increasing Expenditures for Health Care and Investments in Regenerative Medicines Increasing Geriatric Population Increasing Product Approvals and Launches R&D for Stem and Gene Therapies Market Restraints Stringent Government Regulatory Settings in R&D Market Opportunities Growing Pipeline for Regenerative Medicines Covid-19 Impact Analysis Impact of Covid-19 on the Market for Cell and Gene Therapies and Regenerative Medicine for Bone and Joint Applications Direct Impact on Clinical Trials in Cell and Gene Therapy Post-Covid-19 Effect on Regenerative Medicine for Bones and Joint Applications Chapter 6 Market Breakdown by Technology Global Market, by Technology Biomaterials Biomaterials for Regeneration Market Size and Forecast Tissue Engineering Market Size and Forecast Stem Cell Therapy Market Size and Forecast Chapter 7 Market Breakdown by Application Global Market, by Application Allogeneic Bones Autogenic Bones Bone Graft Substitutes Osteoarticular Diseases Other Diseases Chapter 8 Market Breakdown by Region Global Market, by Region North America United States Canada Europe Germany France United Kingdom Italy Russia Spain Rest of Europe Asia-Pacific China Japan Australia India Rest of Asia-Pacific Rest of the World Market Size and Forecast Chapter 9 Regulatory Aspects New and Accelerated Approvals of Regenerative Medicine for Bones and Joint Applications Chapter 10 Patent Review/New Developments Patent Analysis, by Year Chapter 11 Competitive Landscape Mergers, Acquisitions, and Agreements Product Launches Manufacturers of Regenerative Medicine for Bones and Joint Applications and Their Market Share Analysis Chapter 12 Company Profiles Anika Therapeutics Inc. Arthrex Inc. Baxter International Inc. Bioventus Conmed Corp. Depuy Synthes Products Inc. (Part of Johnson & Johnson) Medtronic plc Royal Biologics Seikagaku Corp. Smith & Nephew plc Stryker Corp. Zimmer Biomet Holdings Inc. For more information about this report visit About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Media Contact: Research and Markets Laura Wood, Senior Manager [email protected] For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716 Logo: SOURCE Research and Markets

PARSIPPANY, N.J.--( BUSINESS WIRE )--Ferring Pharmaceuticals (Ferring) announced that its clinical development partner, Seikagaku Corporation (Seikagaku), achieved positive topline results for its registrational Phase 3 clinical trial of SI-6603, an investigational treatment for lumbar disc herniation (generic name: Condoliase). The study was a randomized, double-blind, controlled, parallel-group, comparative study of SI-6603 in 352 patients with lumbar disc herniation. The primary endpoint for the trial was met. SI-6603 showed statistically significant improvement in worst leg pain score, as assessed by a 100 mm Visual Analog Scale (VAS), versus control at 13 weeks after injection. SI-6603 was generally well-tolerated. Based on the positive study outcome, Seikagaku plans to proceed with preparation for a Biologics License Application (BLA) to the U.S. Food & Drug Administration (FDA). Ferring plans to commercialize the product in the United States and has received further rights to develop, register and commercialize SI-6603 worldwide, excluding Japan. “In the United States, 2-3% of the population suffers from radicular leg pain or sciatica caused by lumbar disc herniation 1 and current pharmacological treatment options are inadequate,” said Elizabeth Garner, MD, MPH, Chief Scientific Officer, Ferring USA. “The positive topline results offer the hope of a non-surgical treatment option for patients and their healthcare providers.” About SI-6603 SI-6603, which contains Condoliase as its active pharmaceutical ingredient, is intended to treat lumbar disc herniation via a single, direct intradiscal injection. It has the potential benefit of not requiring general anesthesia and being less invasive to patients than surgical treatment. Marketing approval for SI-6603 in Japan was obtained from the Japanese Ministry of Health, Labour and Welfare in March 2018, and SI-6603 has been marketed as HERNICORE ® 1.25 units for intradiscal injection through Seikagaku Corporation’s Japanese sales partner Kaken Pharmaceutical Co., Ltd. (Tokyo, Japan) since August 1, 2018. 2 About Ferring Pharmaceuticals Ferring Pharmaceuticals is a research-driven, specialty biopharmaceutical group committed to helping people around the world build families and live better lives. In the United States, Ferring is a leader in reproductive medicine and maternal health, uro-oncology and in specialty areas within gastroenterology, including microbiome therapeutics, and orthopaedics. For more information, call 1-888-FERRING (1-888-337-7464) or visit www.ferringusa.com . References: 1 Vialle LR, Vialle EN, Suárez Henao JE, Giraldo G. LUMBAR DISC HERNIATION. Rev Bras Ortop . 2015 Nov 16;45(1):17-22. doi: 10.1016/S2255-4971(15)30211-1. PMID: 27019834; PMCID: PMC4799068. 2 Press Release. Seikagaku and Kaken Announce the Launch of HERNICORE ® 1.25 Units for Intradiscal Injection in Japan. July 31,2018. Available at: https://www.seikagaku.co.jp/en/news/news-6617037418084939174/main/0/link/20180731-e.pdf . Accessed May 24, 2023.